transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Författare och institution:
K. A. Phillips (-); M. M. Regan (-); K. Ribi (-); P. A. Francis (-); F. Puglisi (-); M. Bellet (-); S. Spazzapan (-); Per Karlsson (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för onkologi); D. R. Budman (-); K. Zaman (-); E. A. Abdi (-); S. M. Domchek (-); Y. Feng (-); K. N. Price (-); A. S. Coates (-); R. D. Gelber (-); P. Maruff (-); F. Boyle (-); J. F. Forbes (-); T. Ahles (-); G. F. Fleming (-); J. Bernhard (-); Soft Investigators Co (-)
Publicerad i:
British Journal of Cancer, 114 ( 9 ) s. 956-964
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen + OFS, exemestane + OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen + OFS and exemestane + OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean +/- s.d., -0.21 +/- 0.92 vs -0.04 +/- 0.49, respectively, P = 0.71, effect size = -0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Cancer och onkologi
breast cancer, ovarian function, cognitive function, quality of life, premenopausal, GnRH agonist, tamoxifen, exemestane, endocrine therapy, premenopausal women, randomized-trials, young-women, impairment, chemotherapy, exemestane, menopause, performance, alprazolam, Oncology
Postens nummer:
Posten skapad:
2016-05-31 09:30

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007